Drug · CHEMBL103

PROGESTERONE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. PROGESTERONE. Drugs and targets, record CHEMBL103. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL103

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: PROGESTERONE; ChEMBL
ChEMBL ID: CHEMBL103; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Crinone, Cyclogest, Endometrin, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone component of bijuva, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan; ChEMBL
Other names: NSC-64377, NSC-9704, Progesterona, Progesterone, micronized, Progesteronum, U 3672; ChEMBL
DrugBank: DB00396; DrugBank
InChIKey: RJKFOVLPORLFTN-LEKSSAKUSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 69 diseases, from DailyMed, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
PGR	Progesterone receptor	Progesterone receptor agonist	AGONIST	https://conductscience.org/library/genes/5241

Source ChEMBL

Diseases69

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Infertility	Approval	PMDA	59	58	https://conductscience.org/library/drugs?q=HP_0000789
polycystic ovary syndrome	Phase 2/3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0008487
infertility disorder	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0005047
endometrial cancer	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0011962
menopause	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=GO_0042697
nicotine dependence	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0008575
pregnancy	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=EFO_0002950
premature birth	Phase 2/3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=EFO_0003917
amenorrhea	Approval	DailyMed and TTD	6	3	https://conductscience.org/library/drugs?q=MONDO_0001836
breast cancer	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0007254

1 to 10 of 69Source Open Targets

See all 69 diseases

Trials421

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01942668	A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms	Phase 3	1,845	2019-05-06	progesterone	Its name	ClinicalTrials.gov
NCT02518594	A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix	Phase 3	1,311	2026-03-10	progesterone	Its name	ClinicalTrials.gov
NCT01143064	Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury	Phase 3	1,195	2024-10-02	progesterone	Its name	ClinicalTrials.gov
NCT01850030	A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization	Phase 3	1,070	2018-01-02	progesterone	Its name	ClinicalTrials.gov
NCT02491437	A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)	Phase 3	1,034	2019-10-01	progesterone	Its name	ClinicalTrials.gov
NCT00822900	Progesterone for the Treatment of Traumatic Brain Injury III	Phase 3	882	2015-07-03	progesterone	Its name	ClinicalTrials.gov
NCT00828191	Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)	Phase 3	800	2012-12-26	progesterone	Its name	ClinicalTrials.gov
NCT00827983	Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)	Phase 3	683	2012-12-26	progesterone	Its name	ClinicalTrials.gov
NCT02524561	KEEPS Mammographic Density And Breast Health Ancillary Study		517	2017-03-08	progesterone	Its name	ClinicalTrials.gov
NCT00656201	Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)	Phase 4	468	2011-09-20	progesterone	Its name	ClinicalTrials.gov

1 to 10 of 421

See all 421 trials

Comparisons in its trials135

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
BHR-100 vs Placebo: deaths from any cause	109 of 596	95 of 583	1,179	NCT01143064	Trial comparisons
BHR-100 vs Placebo: serious adverse events	224 of 596	214 of 583	1,179	NCT01143064	Trial comparisons
Dydrogesterone 30 mg vs Micronized Progesterone 600 mg: serious adverse events	56 of 518	68 of 511	1,029	NCT01850030	Trial comparisons
Progesterone vs Placebo: serious adverse events	246 of 442	251 of 440	882	NCT00822900	Trial comparisons
Progesterone SC vs Progesterone Tablets: serious adverse events	0 of 400	0 of 400	800	NCT00828191	Trial comparisons
Progesterone SC vs Progesterone Vaginal Gel: serious adverse events	14 of 338	20 of 344	682	NCT00827983	Trial comparisons
Expectant Mothers - Corifollitropin Alfa 150 µg vs Fetuses Present at 10 Weeks After Fresh ET in Base Study: serious adverse events	145 of 268	84 of 315	583	NCT00702234	Trial comparisons
Prochieve vs Placebo: serious adverse events	97 of 235	98 of 224	459	NCT00615550	Trial comparisons
Prochieve vs Placebo: Number of Neonates Who Died.	3 of 235	5 of 223	458	NCT00615550	Trial comparisons
Prochieve vs Placebo: Number of Participants With Birth <=32 6/7 Weeks Gestation.	21 of 235	36 of 223	458	NCT00615550	Trial comparisons

1 to 10 of 135

See all 135 comparisons in its trials

Papers from its trials267

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39982935	RESULT	2	PubMed
39815396	RESULT	1	PubMed
39603526	RESULT	1	PubMed
38735231	RESULT	1	PubMed
37535682	RESULT	1	PubMed
36999666	RESULT	1	PubMed
36781098	RESULT	1	PubMed
36574915	RESULT	1	PubMed
36518987	RESULT	1	PubMed
36171152	RESULT	1	PubMed

1 to 10 of 267

See all 267 papers from its trials

Tests in its trials10

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Monetary Incentive Delay	3	3	ConductCognition
Dot-Probe Task	2	1	ConductCognition
Go/No-Go Task	2	1	ConductCognition
Point Subtraction Aggression Task	2	1	ConductCognition
Posner Cueing	2	1	ConductCognition
Verbal Learning	2	0	ConductCognition
Delay Discounting	1	1	ConductCognition
Effort for Rewards Task	1	0	ConductCognition
Stroop Color-Word Test	1	0	ConductCognition
Symbol Coding	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL103

GET https://conductscience.org/api/drugs/v1/CHEMBL103/diseases?page=2

API reference For AI assistants